AIP
TVRD

Ahrens Investment Partners’s Tvardi Therapeutics TVRD Stock Holding History

Ahrens Investment Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$3.44K Buy
+19
New +$6.36K ﹤0.01% 822
2022
Q3 		– Sell
-33
Closed -$11K – 960
2022
Q2 		$11K Hold
33
– – ﹤0.01% 634
2022
Q1 		$15K Hold
33
– – ﹤0.01% 644
2021
Q4 		$15K Buy
+33
New +$16.6K 0.01% 653

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ahrens Investment Partners's TVRD Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Tvardi Therapeutics (TVRD) in Q1 2023: 19 shares worth $3.44K. The stake represents ﹤0.01% of the portfolio and ranks #822 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in TVRD as recently as Q2 2022.

Ahrens Investment Partners first reported a position in TVRD in Q4 2021 and has held it in 4 quarters since. The position peaked at $15K in Q1 2022. 163 funds tracked by Wall St. Rank hold TVRD as of Q1 2023.

  • Ahrens Investment Partners held 19 shares of Tvardi Therapeutics worth $3.44K as of Q1 2023.
  • Tvardi Therapeutics was a new Ahrens Investment Partners position in Q1 2023.
  • Tvardi Therapeutics made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #822 holding.
  • Ahrens Investment Partners first reported a position in Tvardi Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Ahrens Investment Partners's Tvardi Therapeutics position peaked at $15K in Q1 2022.
  • 163 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.